Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Aza-TdC in Patients With Advanced Solid Tumors
NCT03366116Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2018
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NTX-301 in solid tumor, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at Cycle 2. Started Nov 2018; status: recruiting.
02
Drugs
NTX-301
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03366116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03366116.